A Practical Guide to Early Intervention for Acne Hyperpigmentation

18 October 2026

A new expert consensus offers dermatologists practical recommendations for managing acne-associated hyperpigmentation and scarring in patients with skin of color. The condition, which can persist for months or years without treatment, is both a cosmetic concern and a predictor of permanent damage.

Acne-associated Macular Hyperpigmentation (AMH) is a common sequela of inflammatory acne, particularly in the Black and Asian populations. Post-inflammatory hyperpigmentation (PIH) in these skin types is more prominent, prolonged, and susceptible to scarring. Yet the evidence base for treatment has been fragmented, with few large trials to guide best practices.

The Driving Need for Early Intervention

AMH occurs when excess melanin, triggered by inflammation from acne lesions, accumulates in the epidermis and dermis. In darker skin tones, this response is exaggerated, and PIH lingers. This not only affects appearance but strongly correlates with scarring likelihood, another concern especially in pigmented skin. "Early intervention is the key," said dermatologist Dr. Jones, lead author of the consensus published in *JAAD.* "The hyperpigmentation itself can persist for years, and it also exposes the patient to a higher risk of permanent scarring."

Recommendations to Watch

The consensus panel, convened using a modified Delphi process, identified first-line and adjunctive therapies for AMH. The primary recommendations:

- Topical retinoid plus benzoyl peroxide as first-line acne control

- Hydroquinone, azelaic acid, and antioxidants as adjuvant depigmenting agents

- Chemical peels as an alternative second-line option

- Laser therapy for recalcitrant cases

Laser treatments tend to cause irritation in darker skin, so pigment laser toning requires careful balancing of the correct wavelength and energy range.

"Patients want to see a difference as soon as possible," said Dr. Patel, a panel member. "So we encourage practitioners to start with the retinoid plus benzoyl peroxide in combination with photoprotection. Photosensitivity is a factor for most of these skin types."

Second-line approaches are selected based on patient tolerance, PIH severity, and risk of irritation. Hydroquinone is a potent depigmenting agent but can cause skin irritation and temporarily worsen hyperpigmentation. Chemical peels and laser treatments offer effectiveness for recalcitrant lesions but should be used with caution in darker skin tones.

Study and Review Support

The recommendations integrate insights from multiple expert reviews and systematic studies. A 2024 analysis of 48 studies found that PIH in skin of color is often triggered by inflammatory conditions like acne, frequently affecting the face. Topical retinoids were the most commonly reported therapy, showing partial improvement in 85% of cases. Laser therapy also demonstrated some efficacy.

Noted Dr. Singh, another panelist, "We have emerging evidence to support some of these treatments, but there's still a lot not yet answered by randomized trials. That's why we needed to consolidate the expert opinion and review data into a practical set of guidelines."

Looking Ahead

The panel offers a notably detailed consensus on a common complication of acne in skin of color. Next steps will be to accumulate more data on treatment efficacy, sequelae, and combination approaches. "We're laying down a baseline here, but this will need to evolve alongside the clinical evidence," said Dr. Patel. As Jones adds, "And we're encouraging more studies into laser safety and robust data on acne itself in skin of color, since that's the foundation behind all of this."

In the near term, the consensus provides a framework for dermatologists to select and monitor therapies for acne hyperpigmentation in a responsible, personalized way. With careful consideration of treatment tolerance and prevention of complications, clinicians can make substantial progress, shortening the physical and emotional burden of this condition.